Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MEJ.0000000000001109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Marstacimab: First Approval.
Drugs
December 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Marstacimab (marstacimab-hncq; HYMPAVZI™) is a subcutaneously administered human monoclonal immunoglobulin G1 antibody against tissue factor pathway inhibitor (TFPI) that is being developed by Pfizer for the treatment of hemophilia A and B. Marstacimab received its first approval on 11 October 2024 in the USA. It was approved for use as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
View Article and Find Full Text PDFComment to: Subcutaneous fat thickness predicts postoperative seroma following laparoscopic total extra-peritoneal hernioplasty.
Hernia
December 2024
Department of General Surgery, The People's Hospital of Yuhuan, Taizhou, Zhejiang, 317600, PR China.
Comment to: Subcutaneous fat thickness predicts postoperative seroma following laparoscopic total extra-peritoneal hernioplasty.
Hernia
December 2024
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Hunan University of Medicine, Yushi Road 225, Huaihua, 418000, Hunan, China.
The Impact of Fu's Subcutaneous Needling on Lower Limb Muscle Stiffness in Knee Osteoarthritis Patients: Study Protocol for a Pilot Randomized Controlled Trial [Response to Letter].
J Pain Res
November 2024
Department of Physical Medicine and Rehabilitation, China Medical University Hospital, China Medical University, Taichung, 404332, Taiwan.
Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).
Rev Med Interne
January 2025
Service de Médecine Interne et Immunologie Clinique, CHU de Dijon, Dijon, France.
Article Synopsis
- The purpose of this project was to update the 2016 recommendations regarding the management of immunosuppressants or biologics in patients with giant cell arteritis (GCA).
- A task force of 18 physicians developed 26 validated recommendations after thorough discussion and a >85% consensus process.
- Key recommendations include using subcutaneous tocilizumab (TCZ) as a first-line treatment when glucocorticoid-sparing is needed, initiating TCZ at diagnosis for patients with specific high-risk conditions, and considering TCZ or methotrexate if glucocorticoid discontinuation is not feasible after 12 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!